The future leaves
signals in time.

Scientists have found that unusually small cancer cells carrying extra chromosomes can be far more aggressive than larger ones, growing faster, spreading more readily and resisting common treatments. The finding could help explain why some tumors are especially dangerous and may offer a new way to predict cancer outcomes.

The CEO of Compass Pathways said the psychedelics company, whose psychedelic therapy is set for regulatory review this year, is prepared to "go slow before we go fast."

A major study found that several cancers are rising faster among younger adults in England, even as smoking, diet, and other established risk factors have generally improved. Excess weight explains only part of the increase, and scientists are searching for other possible causes, including gut microbiome changes and early-life exposures.

According to Ars Technica, things are finally looking up for NASA's first missions to Venus in a generation. "This is great news for us. We're staffing up. We're accelerating," the team said. Further details were not provided in the available context.

Cornell University researchers report the first genetically confirmed cases of Marfan syndrome in domestic felines, found in two unusually long-legged cats. The brothers carried two altered copies of a gene linked to the rare connective tissue disorder, which can affect the eyes, heart, and blood vessels; the cats survived to adulthood because the mutation retained some normal function.

Researchers at UC Santa Cruz are highlighting a largely overlooked peptide called P3 that could also play a role in Alzheimer's disease. Previously believed harmless, P3 can reportedly form harmful-looking protein clumps even faster than amyloid beta and may damage brain cells. Decades of research and billions in treatments have focused on amyloid beta, often with disappointing results.

Scientists have discovered a protein that may help harmful aging cells hide from the immune system, allowing them to accumulate and fuel age-related health problems. In mouse experiments, blocking the protein reduced these cells and inflammation while improving blood sugar regulation and strength. The finding, based on animal models, offers a promising new direction for anti-aging research.

A new knee arthritis treatment uses tiny dissolvable particles to block abnormal blood vessels, easing inflammation and pain without joint replacement surgery. In a study of 194 patients, 80% experienced clinically meaningful pain relief lasting at least 12 months.

A phase 1 trial of personalized neoantigen-targeting cancer vaccines in ovarian cancer was published in Nature Medicine. The supplied context does not include trial results or efficacy data.

A randomized phase 2 trial published in Nature Medicine examined talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer. No trial results or efficacy data are provided in the available information.

Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences. The item does not provide specific safety data or conclusions.

Scientists have created a new coating for mitochondria that preserves their ability to produce energy, potentially opening the door to new treatments for diseases involving these cellular powerhouses. The technology could one day help transfer healthy mitochondria into damaged cells, though its effectiveness in transplantation remains unproven.

The FDA has approved Zanvastro, the first drug directly targeting Alexander disease, a rare neurological disorder affecting fewer than one in a million people. According to the report, the drug, developed through decades of research, showed promising clinical trial results, stabilizing motor function and even improving movement in some patients.

According to Nature Biotechnology, proteomic aging clocks are going to trial. Further details about the trials are not provided in the available context.

A Nature Biotechnology paper reports using ligand-directed lipid nanoparticles to engineer CAR natural killer cells in vivo for immunotherapy. The supplied context does not include trial stage or outcome details.

A Nature Medicine study characterized the onset and progression of cancer cachexia using routine clinical data. The available information does not include specific methods, sample details, or findings.

Scientists found that declining levels of the protein Menin may help drive aging; restoring it in older mice reversed several age-related changes within 30 days. Supplementing with the amino acid D-serine improved memory and learning in mice, suggesting a potential approach to age-related cognitive decline—evidence so far comes from mouse models only.